

Valuation of ASCs and OBLs Part I: Distinctions

Introduction

Until approximately 40 years ago, virtually all surgeries were performed in hospitals.¹ Since the 1970s, however, the outpatient services industry has grown at a steady pace, precipitated in part by the *American Medical Association's* (AMA's) 1971 adoption of a resolution endorsing the concept of outpatient surgery under general and local anesthesia for selected procedures and patients.²

This resulting shift to outpatient care has resulted in the advent of a growing number of diverse outpatient officebased facilities tailored to meet the accelerated growth in demand for healthcare services, leading to the establishment of, among other enterprises, ambulatory surgery centers (ASCs), and, more recently, officebased laboratories (OBLs). Currently, there are nearly 6,000 ASCs³ and nearly 700 OBLs⁴ in the U.S.

At the same time, this rapid increase has resulted in increased regulatory scrutiny of the formation, ownership, alignment, and transactions related to these outpatient entities. Consequently, it is important for those involved in any prospective transaction (or formation) to understand the differences between these two types of outpatient facilities, and the implications thereof.

This article is the first in a four-part series and will focus on the characteristics of and general trends related to ASCs and OBLs.

Defining ASCs

ASCs are distinct, Medicare-certified outpatient healthcare facilities that provide services to patients who do not require inpatient hospital admission and a stay lasting more than 24 hours.⁵ ASCs may be classified as *single specialty* or *multi-specialty*, and may be owned by hospitals, physicians, or other healthcare enterprises. These enterprises are reimbursed by Medicare under their own separate prospective payment system.⁶

Since their inception more than four decades ago, ASCs have played an increasingly crucial role in the medical community.⁷ Physicians are attracted to ASCs due to the ability to set and maintain their own schedule, customize their surgical environments, and use specialized staff, which minimizes turnaround time and maximizes the number of procedures that can be efficiently and conveniently performed.⁸ In short, physicians typically

find greater professional autonomy over their work environment and the quality of care provided in ASCs.⁹

As noted above, ASCs have increased in number over recent years, due in part to the potential for higher quality of care and greater efficiencies provided at these facilities, derived from technological and surgical procedure innovations.¹⁰ In particular, improved anesthesia and utilization of safe, minimally invasive techniques has driven this migration toward ASCs.¹¹ Patients report preference for ASCs due to their lower copays, convenient locations, short wait times, and ease of scheduling.¹² This growth, however, has slowed in recent years. From 2000 to 2006, the number of ASCs grew from about 3,000 to nearly 4,700, over a 50% increase.¹³ By contrast, there was only about a 20% growth in the number of ASCs between 2006 and 2018.14 The ASC industry was estimated to produce \$29.5 billion in revenue in 2020, including \$5.8 billion in profits.¹⁵ In 2020, the global ASC market was valued at \$84.4 billion, with nearly half of the ASC market share in North America.¹⁶ From 2019 to 2029, this industry is expected to grow at a compound annual growth rate (CAGR) of approximately 6%.17

Concentration in the ASC industry is low, with the four largest ASCs expected to generate less than 15% of total revenue.¹⁸ However, experts expect industry consolidation to increase over the next five years as the number of partnerships, including those with hospitals, and ASC acquisitions continue to rise.¹⁹ Most hospitals, in fact, now provide outpatient services (96% as of 2019) and outpatient surgery (93% as of 2019).²⁰ The prevalence of these outpatient procedures provided by hospitals has increased over the past ten years, with outpatient surgery seeing especially high surges.²¹

Defining OBLs

OBLs, also known as office-based endovascular centers, access centers, or office interventional suites, are physician offices wherein a number of services are offered. Similar to ASCs, OBLs can be *single specialty* or *multi-specialty* and can have a number of ownership structures. However, unlike ASCs, OBL procedures (because they are located in a physician office) are reimbursed under the Medicare Physician Fee Schedule.²²

OBLs are typically operated and utilized by vascular surgeons, interventional radiologists, cardiologists, or other specialists, and services provided include: cardiovascular, endovascular, venous, and non-vascular services; cardiac procedures, such as diagnostic coronary angiograms, coronary stenting, electrophysiology services; device implants, including pacemakers, defibrillators, loop recorders, and biventricular pacers; lower extremity endovascular revascularizations, such as chronic total occlusion and complex limb salvage procedures; renal and mesenteric revascularizations; and, subclavian stenting.²³ Of these procedures, peripheral vascular intervention. cardiac services, and interventional radiology made up the majority of the OBL market share in 2019.24

While slower to materialize than ASCs, OBLs have increased rapidly over the past few years, for reasons similar to ASCs, e.g., opportunities for physician ownership, the "expedient patient experience"²⁵ and "favorable outpatient procedural reimbursement."²⁶

In 2020, the global OBL market was valued at \$9 billion.²⁷ Similar to ASCs, an increasing focus on outpatient procedures (due to their cost-saving potential) will also likely lead to an increase in OBLs. From 2020 to 2027, this industry is expected to grow by a CAGR of approximately 7%.²⁸

Conclusion

The number of healthcare services provided at ASCs and OBLs continues to increase due in part to the rapidly evolving technological advances that allow many services and procedures to be performed in a safe, high quality, and, often, less costly environment than at many inpatient providers. The healthcare industry's increasing emphasis on value-based reimbursement (VBR) will likely only lead to greater investment and growth in these two industries in the future.

The next three parts of this series will focus on various issues related to the valuation of ASCs and OBLs. The second installment discuss the regulatory environment in which these enterprises operate, while the third and fourth installments will focus on the value drivers for ASCs and OBLs, respectively.

- 1 "History of ASCs" Ambulatory Surgery Center Association, https://www.ascassociation.org/advancingsurgicalcare/asc/histor yofascs (Accessed 2/4/21).
- 2 Ibid.
- 3 "Number of ASCs Per State" Advancing Surgical Care, May 2020,

https://www.ascassociation.org/advancingsurgicalcare/asc/numb erofascsperstate (Accessed 2/4/21).

- 4 "Outpatient Endovascular and Interventional Society" https://oeisociety.com/ (Accessed 2/4/21).
- 5 "Ambulatory Surgical Center Payment System" Centers for Medicare & Medicaid Services, MLN Fact Sheet, March 2020, https://www.cms.gov/Outreach-and-Education/Medicare-Learning-Network-MLN/MLNProducts/Downloads/AmbSurgCtrFeepymtfctsht508-

MLN/MLNProducts/Downloads/AmbSurgCtrFeepymtfctsht50 09.pdf (Accessed 2/4/21), p. 2.

- 6 *Ibid*, p. 6.
- "Ambulatory Surgery Centers: A Positive Trend in Health Care" Ambulatory Surgery Center Association, 2013, http://higherlogicdownload.s3.amazonaws.com/ASCACONNEC T/142533d1-73af-4211-9238-7f136c02de93/UploadedImages/About%20Us/ASCs%20-%20A%20Positive%20Trend%20in%20Health%20Care.pdf (Accessed 2/4/21), p. 1.
 Ibid
- 8 Ibid
- 9 Ibid; "Chapter 5 Ambulatory Surgical Center Services" In "Report to the Congress: Medicare Payment Policy" Medicare Payment Advisory Commission, March 2020, http://medpac.gov/docs/defaultsource/reports/mar20_entirereport_sec.pdf (Accessed 2/4/21), p. 150.
- 10 Medicare Payment Advisory Commission, March 2020, p. 149.
- 11 Ambulatory Surgery Center Association, 2013, p. 5.
- 12 *Ibid*; Medicare Payment Advisory Commission, March 2020, p. 149-150.
- 13 Ambulatory Surgery Center Association, 2013, p. 5.
- 14 Ibid, p. 5; "Section 7: Ambulatory Care" In: "Health Care Spending and the Medicare Program" Medicare Payment Advisory Commission, July 2020, http://www.medpac.gov/docs/default-source/databook/july2020_databook_sec7_sec.pdf?sfvrsn=0 (Accessed 2/4/21), p. 94.

- 15 "US Industry (Specialized) Report OD5971: Ambulatory Surgery Centers" By Dmitry Diment, IBISWorld, December 2020, p. 7.
- 16 "Ambulatory Surgery Center Market Size, Share & Trends Analysis Report By Application (Orthopedics, Plastic Surgery, Ophthalmology, Gastroenterology, Pain Management), By Region, And Segment Forecasts, 2019 - 2026" Grand View Research, May 2019, https://www.grandviewresearch.com/industry-

analysis/ambulatory-surgery-center-asc-market (Accessed 2/19/21).

- 17 Ibid.
- 18 IBISWorld, December 2020, p. 27.
- 19 Ibid.
- 20 Medicare Payment Advisory Commission, July 2020, p. 90.
- 21 Ibid.
- 22 See, e.g., "Future of vascular surgery is in the office" By Krishna M. Jain, MD, et al., Journal of Vascular Surgery, Vol. 51 (February 2010), p. 509-514.
- 23 "Office-Based Labs: An Evolving Healthcare Model" By Jeffrey G. Carr, Cath Lab Digest, Vol. 25, Issue 11 (November 2017), https://www.cathlabdigest.com/article/Office-Based-Labs-Evolving-Healthcare-Model (Accessed 2/4/21).
- 24 "U.S. Office-based Labs Market Size, Share & Trends Analysis Report By Modality (Single Specialty Labs, Hybrid Labs), By Service, By Specialist, And Segment Forecasts, 2020 – 2027" Grand View Research, December 2020, https://www.grandviewresearch.com/industry-analysis/officebased-labs-obl-market (Accessed 2/4/21).
- 25 "Treatment outcomes and lessons learned from 5134 cases of outpatient office-based endovascular procedures in a vascular surgical practice" By PH Lin, et al., Vascular, Vol. 25, No. 2 (April 2017), available at: https://www.ncbi.nlm.nih.gov/pubmed/27381926 (Accessed

2/4/21), p. 115-22. "The Need for Accreditation of Office-Based Interventional

- 26 "The Need for Accreditation of Office-Based Interventional Vascular Centers" By Peter H. Lin, et al., Annals of Vascular Surgery, Vol. 38 (January 2017), available at: https://www.sciencedirect.com/science/article/abs/pii/S0890509 616306689 (Accessed 2/4/21), p. 332-338.
- 27 "Grand View Research, December 2020.
- 28 Ibid.



(800)FYI - VALU Providing Solutions in the Era of Healthcare Reform

Founded in 1993, HCC is a nationally recognized healthcare economic financial consulting firm

- HCC Home
- Firm Profile
- HCC Services
- HCC Experts
- <u>Clients & Projects</u>
- HCC News
- Upcoming Events
- Contact Us
- Email Us

HCC Services

- <u>Valuation Consulting</u>
- <u>Commercial</u> <u>Reasonableness</u> <u>Opinions</u>
- <u>Commercial Payor</u> <u>Reimbursement</u> <u>Benchmarking</u>
- <u>Litigation Support &</u> <u>Expert Witness</u>
- <u>Financial Feasibility</u> Analysis & Modeling
- <u>Intermediary</u> <u>Services</u>
- <u>Certificate of Need</u>
- <u>ACO Value Metrics</u>
 <u>& Capital Formation</u>
- <u>Strategic Consulting</u>
- <u>Industry Research</u> <u>Services</u>



Todd A. Zigrang, MBA, MHA, CVA, ASA, FACHE, is the President of **HEALTH CAPITAL CONSULTANTS** (HCC), where he focuses on the areas of valuation and financial analysis for hospitals, physician practices, and other healthcare enterprises. Mr. Zigrang has over 25 years of experience providing valuation, financial, transaction and strategic advisory services nationwide in over 2,000 transactions and joint ventures. Mr. Zigrang is also considered an expert in the field

of healthcare compensation for physicians, executives and other professionals.

Mr. Zigrang is the co-author of "*The Adviser's Guide to Healthcare – 2nd Edition*" [2015 – AICPA], numerous chapters in legal treatises and anthologies, and peerreviewed and industry articles such as: *The Accountant's Business Manual* (AICPA); *Valuing Professional Practices and Licenses* (Aspen Publishers); *Valuation Strategies; Business Appraisal Practice*; and, *NACVA QuickRead*. In addition to his contributions as an author, Mr. Zigrang has served as faculty before professional and trade associations such as the American Society of Appraisers (ASA); American Health Lawyers Associate (AHLA); the American Bar Association (ABA); the National Association of Certified Valuators and Analysts (NACVA); Physician Hospitals of America (PHA); the Institute of Business Appraisers (IBA); the Healthcare Financial Management Association (HFMA); and, the CPA Leadership Institute.

Mr. Zigrang holds a Master of Science in Health Administration (MHA) and a Master of Business Administration (MBA) from the University of Missouri at Columbia. He is a Fellow of the American College of Healthcare Executives (FACHE) and holds the Accredited Senior Appraiser (ASA) designation from the American Society of Appraisers, where he has served as President of the St. Louis Chapter, and is current Chair of the ASA Healthcare Special Interest Group (HSIG).



Jessica L. Bailey-Wheaton, Esq., is Senior Vice President and General Counsel of HCC, where she conducts project management and consulting services related to the impact of both federal and state regulations on healthcare exempt organization transactions, and provides research services necessary to support certified opinions of value related to the Fair Market Value and Commercial Reasonableness of transactions related to healthcare enterprises,

assets, and services.

She serves on the editorial boards of NACVA's The Value Examiner and of the American Health Lawyers Association's (AHLA's) Journal of Health & Life Sciences Law. Additionally, she is the current Chair of the American Bar Association's (ABA) Young Lawyers Division (YLD) Health Law Committee and the YLD Liaison for the ABA Health Law Section's Membership Committee. She has previously presented before the ABA, NACVA, and the National Society of Certified Healthcare Business Consultants (NSCHBC).

Ms. Bailey-Wheaton is a member of the Missouri and Illinois Bars and holds a J.D., with a concentration in Health Law, from Saint Louis University School of Law, where she served as Fall Managing Editor for the Journal of Health Law & Policy.



Daniel J. Chen, MSF, CVA, focuses on developing Fair Market Value and Commercial Reasonableness opinions related to healthcare enterprises, assets, and services. In addition he prepares, reviews and analyzes forecasted and pro forma financial statements to determine the most probable future net economic benefit related to healthcare enterprises, assets, and services and applies utilization demand and reimbursement trends to project professional medical revenue

streams and ancillary services and technical component (ASTC) revenue streams. Mr. Chen holds the Certified Valuation Analyst (CVA) designation from NACVA.